ATE326478T1 - Peptidderivat - Google Patents

Peptidderivat

Info

Publication number
ATE326478T1
ATE326478T1 AT01915695T AT01915695T ATE326478T1 AT E326478 T1 ATE326478 T1 AT E326478T1 AT 01915695 T AT01915695 T AT 01915695T AT 01915695 T AT01915695 T AT 01915695T AT E326478 T1 ATE326478 T1 AT E326478T1
Authority
AT
Austria
Prior art keywords
function regulator
regulator
development
present
peptide derivative
Prior art date
Application number
AT01915695T
Other languages
German (de)
English (en)
Inventor
Chieko Kitada
Naoki Nishizawa
Shuji Hinuma
Masaki Hosoya
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ATE326478T1 publication Critical patent/ATE326478T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
AT01915695T 2000-03-23 2001-03-22 Peptidderivat ATE326478T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000087114 2000-03-23
JP2000288891 2000-09-19

Publications (1)

Publication Number Publication Date
ATE326478T1 true ATE326478T1 (de) 2006-06-15

Family

ID=26588465

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01915695T ATE326478T1 (de) 2000-03-23 2001-03-22 Peptidderivat

Country Status (10)

Country Link
US (1) US7635751B2 (https=)
EP (1) EP1270585B1 (https=)
JP (1) JP4786047B2 (https=)
KR (1) KR20020081466A (https=)
CN (1) CN1419563A (https=)
AT (1) ATE326478T1 (https=)
AU (1) AU2001242749A1 (https=)
CA (1) CA2403447A1 (https=)
DE (1) DE60119714T2 (https=)
WO (1) WO2001070769A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003063892A1 (en) * 2002-01-29 2003-08-07 Takeda Chemical Industries, Ltd. Use of apelin
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
WO2007072980A1 (ja) 2005-12-20 2007-06-28 Takeda Pharmaceutical Company Limited アペリンの新規用途
RU2303454C1 (ru) * 2006-06-22 2007-07-27 Общество С Ограниченной Ответственностью "Сиа Пептайдс" Средство, нормализующее репродуктивную функцию у женщин, и способ его получения
EP1903052A3 (en) * 2006-07-28 2008-04-02 Faust Pharmaceuticals SA APJ receptor ligands and uses thereof
WO2013050441A1 (en) 2011-10-05 2013-04-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for inhibiting or preventing platelet aggregation
US9381229B2 (en) 2011-11-28 2016-07-05 Inserm (Institut National De La Sante Et De La Recherche Medicale) Pharmaceutical composition for use in the treatment of dysfunction associated with aging
CN104254540A (zh) * 2012-01-09 2014-12-31 安科治疗公司 Apj受体化合物
US8921307B2 (en) 2012-11-20 2014-12-30 Novartis Ag Synthetic linear apelin mimetics for the treatment of heart failure
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
US20160067347A1 (en) 2012-12-20 2016-03-10 Amgen Inc. Apj receptor agonists and uses thereof
KR20160031551A (ko) 2013-07-25 2016-03-22 노파르티스 아게 심부전의 치료를 위한 시클릭 폴리펩티드
HK1218252A1 (zh) 2013-07-25 2017-02-10 Novartis Ag 合成apelin多肽之生物结合物
CN104436158A (zh) * 2013-09-22 2015-03-25 华中科技大学 Apelin-13在治疗糖尿病肾病中的应用
GB201407532D0 (en) * 2014-04-29 2014-06-11 Univ Ulster Apelin analogues
MA41580A (fr) 2015-01-23 2017-11-29 Novartis Ag Conjugués d'acides gras de l'apeline synthétique présentant une demi-vie améliorée
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
HUE050317T2 (hu) 2015-05-20 2020-11-30 Amgen Inc APJ receptor triazol agonistái
ES2930077T3 (es) 2016-02-15 2022-12-07 Inst Nat Sante Rech Med Apelina para su uso en el tratamiento de la disfunción cognitiva posoperatoria
US9988369B2 (en) 2016-05-03 2018-06-05 Amgen Inc. Heterocyclic triazole compounds as agonists of the APJ receptor
US11046680B1 (en) 2016-11-16 2021-06-29 Amgen Inc. Heteroaryl-substituted triazoles as APJ receptor agonists
WO2018093579A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
US10736883B2 (en) 2016-11-16 2020-08-11 Amgen Inc. Triazole furan compounds as agonists of the APJ receptor
WO2018093576A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Alkyl substituted triazole compounds as agonists of the apj receptor
WO2018093577A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the apj receptor
EP3541803B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
MA50509A (fr) 2017-11-03 2021-06-02 Amgen Inc Agonistes de triazole fusionnés du récepteur apj
US11807624B2 (en) 2018-05-01 2023-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the APJ receptor
WO2026007692A1 (zh) * 2024-07-05 2026-01-08 浙江大学 Apelin-13多肽突变体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2118372T3 (es) * 1992-11-17 1998-09-16 Icos Corp Nuevos receptores siete transmembrana v28.
KR20010033601A (ko) * 1997-12-24 2001-04-25 다케다 야쿠힌 고교 가부시키가이샤 폴리펩티드, 그의 제법 및 용도
US6475718B2 (en) * 1998-09-08 2002-11-05 Schering Aktiengesellschaft Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus
AU5759399A (en) * 1998-09-25 2000-04-17 Takeda Chemical Industries Ltd. Peptide derivative

Also Published As

Publication number Publication date
EP1270585A4 (en) 2004-12-15
US7635751B2 (en) 2009-12-22
EP1270585B1 (en) 2006-05-17
JP4786047B2 (ja) 2011-10-05
KR20020081466A (ko) 2002-10-26
JP2002167397A (ja) 2002-06-11
CN1419563A (zh) 2003-05-21
DE60119714D1 (de) 2006-06-22
WO2001070769A1 (fr) 2001-09-27
DE60119714T2 (de) 2006-09-07
CA2403447A1 (en) 2001-09-27
US20040116336A1 (en) 2004-06-17
AU2001242749A1 (en) 2001-10-03
EP1270585A1 (en) 2003-01-02

Similar Documents

Publication Publication Date Title
DE60119714D1 (de) Peptidderivat
SE9901379D0 (sv) Receptor structures
SE8904087L (sv) Peptide derivates
DE69638023D1 (de) Nukleotid- und proteinsequenzen von delta-genen von vertebraten und darauf basierende methoden
NO961115D0 (no) Humane metabotrope glutamatreseptorsubtyper (HMR4, HMR6, HMR7) og relaterte DNA forbindelser
DE60025832D1 (de) Mehrere zytokin-antikörper komplexen
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
WO2000034317A3 (en) Method for reducing immunogenicity of proteins
ATE234859T1 (de) Peptid-derivat
DE69636437D1 (de) Ligand polypeptide für hypophyse g-protein gekoppeltes rezeptor-protein, deren herstellung und anwendung
MXPA02008239A (es) Gen humano de la esquizofrenia.
PT877803E (pt) Receptor da proteina ob e composicoes e metodos afins
DE68925275D1 (de) Endotoxin-bindeprotein und dessen verwendung
PT996726E (pt) Proteina de membrana de celulas t (tirc7) peptidos e anticorpos dela derivados e suas utilizacoes
ATE196775T1 (de) Gereinigte flt3 liganden von saeugentieren, agonisten und antagonisten davon
DE69317886D1 (de) Neue propoxyphenderivate sowie deren protein-und polypeptidlabels und-konjugate
EP0635016A4 (en) BENZODIAZEPINE DERIVATIVES AND THEIR CONJUGATES WITH PROTEINS AND POLYPEPTIDES.
WO1999042127A3 (en) Receptor derived peptides as modulators of receptor activity
DE60330680D1 (de) Transferrin-fusionsproteinbibliotheken
WO2001064876A3 (en) Human schizophrenia gene
DE69611037D1 (de) Methadonderivate und protein- und polypeptid-methadonkonjugate und markierte verbindungen
DK0972781T3 (da) Protein S-polypeptider og anvendelser deraf
WO2003044160A3 (en) Novel molecules of the card related protein family and uses thereof
IT8921396A0 (it) Procedimento per la sintesi di peptidi preventivamente identificati come siti di interazione di proteine interagenti.
HK1027837A (en) Diagnosis and treatment of diseases using anti-t-cell receptor vbeta antibodies or peptides which are recognized by said antibodies, and endocrine secretion regulatory protein 1 (esrp1)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties